Cowen and Company’s Ginkgo Bioworks DNA Stock Holding History

Cowen and Company’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-12,500	Closed	-$102K	–	101
2024 Q3	$102K	Hold	12,500	–	–	﹤0.01%	284
2024 Q2	$167K	Buy	+12,500	New	+$373K	﹤0.01%	230

Other funds holding DNA

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Cowen and Company's DNA Position: Q4 2024 in Review

Cowen and Company sold out of Ginkgo Bioworks (DNA) in Q4 2024, closing a stake of 12,500 shares — an estimated $102K sold.

Cowen and Company first reported a position in DNA in Q2 2024 and held it in 2 quarters. The position peaked at $167K in Q2 2024. 165 funds tracked by Wall St. Rank hold DNA as of Q4 2024.

Cowen and Company reported no remaining Ginkgo Bioworks position as of Q4 2024 after selling out during the quarter.
Cowen and Company sold 12,500 Ginkgo Bioworks shares in Q4 2024, an estimated $102K.
Cowen and Company first reported a position in Ginkgo Bioworks in Q2 2024 and held it in 2 quarters.
Cowen and Company's Ginkgo Bioworks position peaked at $167K in Q2 2024.
165 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.